MorphoSys (NASDAQ:MOR – Get Rating) had its price target cut by investment analysts at JMP Securities from $32.00 to $15.00 in a research report issued to clients and investors on Friday, The Fly reports. The brokerage presently has a “market outperform” rating on the stock. JMP Securities’ price objective points to a potential upside of 270.37% from the stock’s current price.
Several other analysts also recently commented on the stock. Deutsche Bank Aktiengesellschaft downgraded shares of MorphoSys from a “hold” rating to a “sell” rating in a research report on Monday, October 24th. Morgan Stanley upped their price target on shares of MorphoSys from €26.00 ($26.80) to €28.00 ($28.87) and gave the company an “equal weight” rating in a research report on Friday, July 29th. Citigroup cut shares of MorphoSys from a “neutral” rating to a “sell” rating in a research note on Tuesday, November 15th. Finally, Stifel Nicolaus cut shares of MorphoSys from a “buy” rating to a “hold” rating in a research note on Tuesday, November 15th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $26.00.
MorphoSys Stock Up 1.5 %
Shares of NASDAQ:MOR opened at $4.05 on Friday. The firm has a 50 day simple moving average of $4.95 and a 200-day simple moving average of $5.08. MorphoSys has a twelve month low of $3.70 and a twelve month high of $10.49. The company has a market capitalization of $554.57 million, a PE ratio of -0.57 and a beta of 0.99. The company has a current ratio of 2.98, a quick ratio of 2.91 and a debt-to-equity ratio of 2.01.
Institutional Investors Weigh In On MorphoSys
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.
- Get a free copy of the StockNews.com research report on MorphoSys (MOR)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.